Welcome to our dedicated page for KAMADA SEC filings (Ticker: KMDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kamada Ltd. filings document a foreign private issuer reporting on a global biopharmaceutical business focused on specialty plasma-derived therapies and marketed products for rare and serious conditions. Recent Form 6-K reports include exhibits on financial results, annual guidance, investor presentations, product-supply tenders, and FDA approval of a plasma collection center.
The filings also record ordinary-share dividend actions, withholding-tax procedures tied to Israeli tax rules, and incorporation of certain current reports by reference into Form S-8 registration statements. Kamada files as a Form 20-F issuer, with disclosures covering governance, capital-return actions, commercial portfolio performance and regulatory events affecting plasma collection and product supply.
Kamada Ltd., a global biopharmaceutical company focused on specialty plasma-derived therapies for rare and serious conditions, stated it will release financial results for the second quarter and first half ended June 30, 2026 before U.S. market open on Wednesday, August 12, 2026. Management will hold an investment community conference call at 8:30am Eastern Time that day, accessible via U.S., Israel, and international dial-in numbers and a live webcast.
The company describes a growth strategy built on four pillars: organic expansion of a commercial portfolio that includes six FDA-approved specialty plasma-derived products plus additional hyper-immune and anti-snake venom therapies; distribution of third-party pharmaceuticals and biosimilars in Israel and the MENA region through in-licensing partnerships; ramp-up of plasma collection operations via three FDA-approved U.S. plasma collection centers; and pursuit of mergers, acquisitions, in-licensing and collaborations to enhance its marketed portfolio. FIMI Opportunity Funds is identified as the controlling shareholder, beneficially owning approximately 38% of the outstanding ordinary shares.
Kamada Ltd. entered into a new three-year agreement to supply normal source plasma from its FDA-approved collection centers in Texas to a leading biopharmaceutical company focused on plasma-derived therapies. The agreement is expected to generate approximately $50 million in revenue over three years, with initial commercial sales expected to be recorded in the fourth quarter of 2026.
The plasma will be sourced from Kamada’s centers in Houston and San Antonio, each designed to support a planned capacity of approximately 50,000 liters per year at full capacity. Management states that this agreement supports Kamada’s vertical-integration strategy, the ramp-up of its plasma collection operations, and its multi-year revenue growth objectives, and notes that expected fourth quarter sales are already reflected in current annual guidance.
Kamada Ltd., a biopharmaceutical company focused on specialty plasma-derived therapies, reported new results from an Investigator-Initiated Study of its Cytomegalovirus Immune Globulin (CMVIG) presented at the 2026 ISHLT annual meeting. The translational and observational data, shown in three posters, examined CMV high-risk lung transplant recipients.
In a retrospective clinical analysis, patients who did not receive CMVIG prophylaxis experienced worse clinical outcomes than those who received CMVIG prophylaxis and other CMV serotype groups. A paired immune-cell analysis found fewer activated innate immune cells in patients who received CMVIG. In a non-clinical in-vivo model, CMVIG reduced key innate immune cells after acute lung injury, blunted lung damage, and improved mortality.
These findings, together with a prior five-year study of 324 lung-transplant patients, support a hypothesis that CMVIG may modulate innate immune responses and be associated with improved outcomes in high-risk CMV mismatch lung transplant recipients. Kamada describes this work as part of a broader post-marketing research program intended to support increased utilization of the product.
Kamada Ltd. is calling an Annual General Meeting of Shareholders for August 5, 2026 in Rehovot, Israel, with a June 23, 2026 record date. Shareholders will vote on re-electing seven directors and two external directors, option grants to all director nominees, and an amendment to the 2011 Israeli Share Award Plan’s U.S. Taxpayers Appendix.
The amendment would lift the incentive stock option limit under the U.S. appendix from 500,000 to 550,000 ordinary shares. Investors will also vote on ratifying Kost Forer Gabbay & Kasierer (Ernst & Young Global member) as independent auditors for 2026, while management reviews 2025 financial statements with shareholders.
Kamada Ltd. reported that the FDA approved its new in-house Rapid Fluorescent Focus Inhibition Test (RFFIT) laboratory, used to measure rabies-neutralizing antibodies. The lab supports Anti-Rabies potency testing for the manufacture of the company’s Anti-Rabies immunoglobulin products KEDRAB and KAMRAB.
The RFFIT lab, located at Kamada’s Beit Kama plant in Israel, is part of its quality control network and is described as meeting stringent safety, quality and GMP standards. It was previously approved by Health Canada and the Israeli Ministry of Health. In 2025, sales of KEDRAB and KAMRAB together totaled over $70 million, making them a leading franchise in Kamada’s specialty plasma-derived portfolio.
Kamada Ltd. reported first quarter 2026 revenue of $45.2 million, up about 3% year-over-year, with net income of $4.1 million and adjusted EBITDA of $11.6 million, a solid 26% margin. Results were affected by a temporary shipment delay of a single order that shipped in April.
The company reaffirmed its 2026 guidance for revenue of $200–$205 million and adjusted EBITDA of $50–$53 million, which it notes imply 12% revenue growth and 23% adjusted EBITDA growth versus 2025 midpoints. Management expects a significantly stronger remainder of 2026 driven by its six FDA-approved plasma-derived products, expanding biosimilar distribution in Israel and MENA, and ramp-up of three U.S. plasma collection centers.
As of March 31, 2026, Kamada held $73.1 million in cash, cash equivalents and short-term investments. The board declared a $0.25 per share special cash dividend, totaling about $14.4 million, paid in April 2026.
Kamada Ltd. filed a Form 6-K to announce that it will release financial results for the first quarter ended March 31, 2026, before the U.S. market open on May 13, 2026. Management will host a conference call that day at 8:30am Eastern Time for investors and analysts.
The company is a global biopharmaceutical business focused on specialty plasma-derived therapies for rare and serious conditions. Its strategy centers on organic growth of its commercial portfolio, in-licensing and distribution in Israel and the MENA region, expanding plasma collection operations, and pursuing mergers, acquisitions, and collaboration opportunities. FIMI Opportunity Funds is the controlling shareholder, holding approximately 38% of the outstanding ordinary shares.
KAMADA LTD director Lilach Asher-Topilsky has filed an initial Form 3 detailing existing employee stock option holdings held by a trustee under the company’s 2011 Share Award Plan. The options relate to 6,625 underlying Ordinary Shares at an exercise price of $7.60 and 7,500 underlying Ordinary Shares at $6.17, with tranches vesting in four equal annual installments. The exercise prices were adjusted from $7.85 to $7.60 and from $6.42 to $6.17 following a cash dividend declared on March 11, 2026; no other award terms changed and no new buy or sell transactions are reported.
KAMADA LTD director Uri Botzer filed an initial ownership report showing indirect holdings of employee stock options over Ordinary Shares, held by a trustee under the company’s 2011 Share Award Plan. Each option position relates to 7,500 underlying Ordinary Shares with an exercise price of $5.50 per share and an expiration date of June 22, 2029.
The options vest in four equal installments, with 25% vesting on each of the four anniversaries of the grant date. The exercise price was adjusted from $5.75 to $5.50 under the plan following a cash dividend distribution declared on March 11, 2026. All exercise prices shown in U.S. dollars are convenience conversions from NIS using the Bank of Israel exchange rate as of April 16, 2026.
Kamada Ltd Vice President of Business Development and Strategic Programs, Boris Gorelik, reported routine compensation-related option adjustments held indirectly by a trustee under the company’s 2011 Share Award Plan. On April 7, 2026, he received several employee stock option awards, each for 3,750 Ordinary Shares at an exercise price of $9.13 per share, and returned options with the same share amount but a $9.38 exercise price to the issuer. Footnotes state the exercise prices are presented in U.S. dollars based on an exchange rate as of April 6, 2026, and were adjusted under the plan in connection with a cash dividend distribution, with no other changes to the option terms. These options vest in four equal 25% annual installments from the grant date and expire on February 11, 2027.